(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-1.16%) $1.619
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
Quarter results tomorrow
(bmo 2024-04-29)
Expected move: +/- 0.00%
Live Chart Being Loaded With Signals
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes...
Stats | |
---|---|
Dagens volum | 1 991.00 |
Gjennomsnittsvolum | 6 522.00 |
Markedsverdi | 654.98B |
EPS | €0 ( 2024-02-06 ) |
Neste inntjeningsdato | ( €1.550 ) 2024-04-29 |
Last Dividend | €1.130 ( 2023-08-14 ) |
Next Dividend | €0 ( N/A ) |
P/E | 127.57 |
ATR14 | €0.994 (0.14%) |
Volum Korrelasjon
Eli Lilly and Co Korrelasjon
10 Mest positive korrelasjoner |
---|
10 Mest negative korrelasjoner |
---|
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Eli Lilly and Co Korrelasjon - Valuta/Råvare
Eli Lilly and Co Økonomi
Annual | 2023 |
Omsetning: | €34.12B |
Bruttogevinst: | €27.04B (79.25 %) |
EPS: | €5.82 |
FY | 2023 |
Omsetning: | €34.12B |
Bruttogevinst: | €27.04B (79.25 %) |
EPS: | €5.82 |
FY | 2022 |
Omsetning: | €28.54B |
Bruttogevinst: | €21.91B (76.77 %) |
EPS: | €6.93 |
FY | 2021 |
Omsetning: | €28.32B |
Bruttogevinst: | €21.01B (74.18 %) |
EPS: | €5.83 |
Financial Reports:
No articles found.
Eli Lilly and Co Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
€0.980 (N/A) |
€0.980 (N/A) |
€1.130 (N/A) |
€1.130 (N/A) |
€1.130 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | €0.490 | 2009-05-13 |
Last Dividend | €1.130 | 2023-08-14 |
Next Dividend | €0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 41 | -- |
Total Paid Out | €27.35 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.68 | -- |
Div. Sustainability Score | 5.72 | |
Div.Growth Potential Score | 6.05 | |
Div. Directional Score | 5.89 | -- |
Year | Amount | Yield |
---|
With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
KEL.DE | Ex Dividend Knight | 2023-08-31 | Quarterly | 0 | 0.00% | |
TIMA.DE | Ex Dividend Junior | 2023-05-10 | Annually | 0 | 0.00% | |
DMP.DE | Ex Dividend Knight | 2023-06-15 | Annually | 0 | 0.00% | |
MTE.DE | Ex Dividend Junior | 2023-07-07 | Quarterly | 0 | 0.00% | |
68V.DE | Ex Dividend Knight | 2023-08-07 | Quarterly | 0 | 0.00% | |
WAF.DE | Ex Dividend Junior | 2023-05-08 | Annually | 0 | 0.00% | |
FIE.DE | Ex Dividend Junior | 2023-07-14 | Annually | 0 | 0.00% | |
PAH3.DE | Ex Dividend Knight | 2023-07-03 | Annually | 0 | 0.00% | |
AP2.DE | Ex Dividend Knight | 2023-11-22 | Quarterly | 0 | 0.00% | |
HDI.DE | Ex Dividend Knight | 2023-08-30 | Quarterly | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.154 | 1.500 | 6.93 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0819 | 1.200 | 7.27 | 8.73 | [0 - 0.3] |
returnOnEquityTTM | 0.474 | 1.500 | 5.85 | 8.77 | [0.1 - 1] |
payoutRatioTTM | 0.777 | -1.000 | 2.23 | -2.23 | [0 - 1] |
currentRatioTTM | 0.943 | 0.800 | -0.287 | -0.230 | [1 - 3] |
quickRatioTTM | 0.523 | 0.800 | -1.632 | -1.305 | [0.8 - 2.5] |
cashRatioTTM | 0.103 | 1.500 | -0.537 | -0.806 | [0.2 - 2] |
debtRatioTTM | 0.394 | -1.500 | 3.43 | -5.15 | [0 - 0.6] |
interestCoverageTTM | 15.00 | 1.000 | 5.56 | 5.56 | [3 - 30] |
operatingCashFlowPerShareTTM | 4.47 | 2.00 | 8.51 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | -3.32 | 2.00 | -1.660 | -3.32 | [0 - 20] |
debtEquityRatioTTM | 2.34 | -1.500 | 0.633 | -0.949 | [0 - 2.5] |
grossProfitMarginTTM | 0.792 | 1.000 | 0.126 | 0.126 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.214 | 1.000 | 7.73 | 7.73 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.168 | 1.000 | -0.177 | -0.177 | [0.2 - 2] |
assetTurnoverTTM | 0.533 | 0.800 | 9.78 | 7.82 | [0.5 - 2] |
Total Score | 5.72 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 133.52 | 1.000 | 10.00 | 0 | [1 - 100] |
returnOnEquityTTM | 0.474 | 2.50 | 7.33 | 8.77 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -3.32 | 2.00 | -1.107 | -3.32 | [0 - 30] |
dividendYielPercentageTTM | 0.636 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 4.47 | 2.00 | 8.51 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.777 | 1.500 | 2.23 | -2.23 | [0 - 1] |
pegRatioTTM | 7.68 | 1.500 | 10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.124 | 1.000 | 9.39 | 0 | [0.1 - 0.5] |
Total Score | 6.05 |
Eli Lilly and Co
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.